Deutsche Bank AG Buys Shares of 5,306 ClearPoint Neuro, Inc. $CLPT

Deutsche Bank AG bought a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 5,306 shares of the company’s stock, valued at approximately $63,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in shares of ClearPoint Neuro by 1,070.9% in the fourth quarter. Barclays PLC now owns 66,436 shares of the company’s stock valued at $1,022,000 after buying an additional 60,762 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of ClearPoint Neuro during the 4th quarter valued at $93,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of ClearPoint Neuro in the 4th quarter valued at approximately $1,633,000. Jane Street Group LLC boosted its holdings in shares of ClearPoint Neuro by 119.6% in the 4th quarter. Jane Street Group LLC now owns 222,307 shares of the company’s stock valued at $3,419,000 after purchasing an additional 121,083 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in ClearPoint Neuro by 7.1% during the fourth quarter. Ameriprise Financial Inc. now owns 41,316 shares of the company’s stock worth $635,000 after acquiring an additional 2,742 shares in the last quarter. 30.08% of the stock is owned by institutional investors and hedge funds.

ClearPoint Neuro Price Performance

Shares of NASDAQ CLPT opened at $10.49 on Tuesday. The stock has a fifty day moving average of $11.13 and a 200-day moving average of $12.43. The stock has a market cap of $298.23 million, a PE ratio of -12.95 and a beta of 0.89. ClearPoint Neuro, Inc. has a fifty-two week low of $9.76 and a fifty-two week high of $19.22. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.45 and a current ratio of 7.30.

ClearPoint Neuro (NASDAQ:CLPT) last announced its earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $9.22 million for the quarter, compared to the consensus estimate of $9.20 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Equities research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Stifel Nicolaus increased their target price on ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Wall Street Zen lowered shares of ClearPoint Neuro from a “hold” rating to a “sell” rating in a report on Saturday, July 12th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, ClearPoint Neuro presently has an average rating of “Buy” and a consensus target price of $19.67.

Insider Buying and Selling

In other ClearPoint Neuro news, Director Timothy T. Richards sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $13.28, for a total value of $132,800.00. Following the completion of the transaction, the director directly owned 77,381 shares in the company, valued at approximately $1,027,619.68. This represents a 11.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph Burnett sold 21,247 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $13.29, for a total value of $282,372.63. Following the transaction, the chief executive officer owned 243,522 shares in the company, valued at $3,236,407.38. This trade represents a 8.02% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.11% of the company’s stock.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.